1. 2331 Prognostic value of neutrophil/lymphocyte ratio in intestinal and pancreatic neuroendocrine tumors: exploratory analysis of data from the CLARINET trial of lanreotide depot/autogel. (September 2015) Authors: Grenader, T.; Ruszniewski, P.; Pavel, M.; Cwikła, J.; Phan, A.; Raderer, M.; Sedláčková, E.; Cadiot, G.; Wolin, E.; Capdevila, J.; Wall, L.; Rindi, G.; Lang, A.; Gomez-Panzani, E.; Caplin, M. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S443 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 2370 Relative risk analysis of safety profile of lanreotide autogel/depot vs. placebo in patients with pancreatic and intestinal neuroendocrine tumours. (September 2015) Authors: Phan, A.; Caplin, M.; Pavel, M.; Cwikła, J.; Raderer, M.; Sedláčková, E.; Cadiot, G.; Wolin, E.; Capdevila, J.; Wall, L.; Rindi, G.; Langley, A.; Gomez-Panzani, E.; Ruszniewski, P. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S460 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 2374 Multivariate analysis of progression-free survival in the CLARINET study of lanreotide Autogel/Depot vs placebo identifies prognostic factors in neuroendocrine tumours. (September 2015) Authors: Wolin, E.; Caplin, M.; Pavel, M.; Cwikła, J.; Phan, A.; Raderer, M.; Sedláčková, E.; Cadiot, G.; Capdevila, J.; Wall, L.; Rindi, G.; Langley, A.; Gomez-Panzani, E.; Ruszniewski, P. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S461 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 5LBA Everolimus in advanced nonfunctional neuroendocrine tumors (NET) of lung or gastrointestinal (GI) origin: Efficacy and safety results from the placebo-controlled, double-blind, multicenter, Phase 3 RADIANT-4 study. (September 2015) Authors: Yao, J.; Fazio, N.; Singh, S.; Buzzoni, R.; Carnaghi, C.; Wolin, E.; Tomasek, J.; Raderer, M.; Lahner, H.; Voi, M.; Pacaud, L.; Lincy, J.; Sachs, C.; Valle, J.; Delle Fave, G.; Van Cutsem, E.; Tesselaar, M.E.T.; Shimada, Y.; Oh, D.Y.; Strosberg, J. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S709 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 6LBA 177-Lu-Dotatate significantly improves progression-free survival in patients with midgut neuroendocrine tumours: Results of the phase III NETTER-1 trial. (September 2015) Authors: Strosberg, J.; Wolin, E.; Chasen, B.; Kulke, M.; Bushnell, D.; Caplin, M.; Baum, R.P.; Mittra, E.; Hobday, T.; Hendifar, A.; Oberg, K.; Lopera Sierra, M.; Ruszniewski, P.; Kwekkeboom, D. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S710 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. SP-0570: Neuroendocrine tumours - personalised diagnosis and treatment using radiolabelled peptides. (April 2016) Authors: Baum, R.P.; Strosberg, J.; Wolin, E.; Chasen, B.; Kulke, M.; Bushnell, D.; Caplin, M.; Hobday, T.; Hendifar, A.; Oberg, K.; Lopera Sierra, M.; Kwekkeboom, D.; Ruszniewsk, P.; Krenning, E.; Mittra, E. Journal: Radiotherapy and oncology Issue: Volume 119(2016)Supplement 1 Page Start: S274 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗